(2022). Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort. Atherosclerosis. http://doi.org/10.1016/j.atherosclerosis.2022.07.011.
(2022). Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. http://doi.org/10.1093/eurheartj/ehac056.
(2011). Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction\textendasha hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J. http://doi.org/10.1093/eurheartj/ehr340.
(2013). Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study. Clin Ther. http://doi.org/10.1016/j.clinthera.2012.11.008.
(2016). Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(16)30057-2.
(2016). Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open. http://doi.org/10.1136/bmjopen-2016-011805.
(2017). Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open. http://doi.org/10.1136/bmjopen-2016-013851.
(2018). Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Netw Open. http://doi.org/10.1001/jamanetworkopen.2018.5554.
(2021). Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals. Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwab093.